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Two years survival of primary cardiac 
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Abstract 
Background: Cardiac tumors are a very rare entity. Leiomyosarcoma represents less than 1% of cases.
Case presentation: a 51-year-old woman diagnosed with primary left atrium leiomyosarcoma. She was treated by 
optimal surgery and adjuvant chemotherapy. She is still alive after a follow-up of 24 months without evidence of local 
or distant recurrence.
Conclusions: Cardiac leiomyosarcoma is a rare tumor with a dismal prognosis. Surgery is the mainstay of treatment. 
Adjuvant treatment is still controversial.
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Background
Cardiac tumors are a very rare entity with an incidence of 
0.02%. Only 25% are malignant with a prevalence rang-
ing from 0.001% to 0.28 [1]. Primary cardiac cancers 
are scarcer than cardiac metastases [2]. Most frequent 
histologic types are Angiosarcomas followed by rhab-
domyosarcomas, mesotheliomas and fibrosarcomas. 
Leiomyosarcoma represents less than 1% of cases [3]. 
In spite of improvement of multidisciplinary treatment 
including surgery, chemotherapy and radiotherapy, the 
prognosis remains (Fig. 1) poor with a median survival of 
6 months [3].
This case aimed to describe the clinical, histologi-
cal, therapeutic and prognostic features of this rare 
pathology.
Case report
We present the case of a 51-year-old woman, with past 
medical history of hypertension, who consulted in Septem-
ber 2014 for bilateral lower limb pain and lower extrem-
ity edema since 6 months. The diagnosis of hypertrophic 
osteoarthropathy was suspected. In this context, a CT 
scan revealed a 6 cm defect, involving the right atrium and 
the right inferior pulmonary vein,  which appears mark-
edly enlarged. This aspect evoked a large intracavitary 
thrombus. A transesophageal cardiac ultrasound showed a 
30 ×  26 mm, with little mobility, lobed tumor, in the left 
atrium, connected to the atrial septum. The tumor wasn’t 
obstructive. Cardiac chambers dimensions and pulmonary 
pressure were normal. There was no systolic or diastolic left 
ventricular dysfunction. The patient was referred to a cardi-
ovascular surgeon with a suspected diagnosis of left atrium 
myxoma. Surgery was performed through median sternot-
omy. The patient had a cardiopulmonary bypass (CPB) with 
aortic and bi-caval cannulation. The left atrium was dis-
sected, revealing a voluminous, septal based tumor involv-
ing the right inferior pulmonary vein and the posterior wall 
of the left atrium, suggestive of malignancy. We did a wide 
en bloc excision of the tumor, extended from the posterior 
wall of the left atrium Fig. 2 and inferior pulmonary vein 
to pericardial reflection. Reconstruction of the left atrium 
with two pericardial patches (an anterior septal and pos-
terior parietal) was achieved according to Sutureless de 
lacourt-Gayettechnique. Macroscopic examination showed 
a friable whitish mass measuring 40 × 30 × 30 mm.
Microscopic examination revealed the presence of con-
junctival tumoral proliferation made of spindle cells with 
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a fascicular organization infiltrating myocardial fibers. A 
high mitotic activity was noticed. Surgical margins were 
clear. Immunohistochemical staining showed an intense 
and diffuse positivity of alpha-smooth-muscle actin and 
caldesmon and the negativity of PS100, desmine and 
myogenin. Based on these findings, diagnosis of primary 
cardiac leiomyosarcoma grade 3 according to FNNCLCC 
was confirmed.
Post-operative CT scan revealed no metastases. 
According to a multidisciplinary staff, an adjuvant chem-
otherapy consisting on six cycles of Doxorubicin and 
Ifosfamide was prescribed.
The patient is regularly followed. After a follow-up of 
24  months, she still has no clinical or radiological evi-
dence of recurrence.
Discussion
We presented a rare case of cardiac leiomyosarcoma 
treated by surgery followed by an adjuvant chemotherapy. 
The patient is still alive after a follow-up of 24 months.
Until December 2015, we found only 32 cases of pri-
mary cardiac leiomyosarcoma with available data. In 
most studies, it was defined as tumors originating only 
from cardiac chambers, excluding those located in the 
pericardium and great vessels [4]. Epidemiological, clini-
cal, therapeutic features and outcomes were listed in the 
Table 1.
Median age at diagnosis was 48 with a female predomi-
nance [4].
This tumor has a poor prognosis due essentially to 
advanced stages at presentation. It usually remains 
asymptomatic until advanced stages. Even when it 
becomes symptomatic, presentation is atypical and non 
specific. Symptoms of obstruction especially dyspnea is 
found in 78.1% of cases [4]. Physical examination isn’t 
helpful no more. In our case, the patient was asympto-
matic and the diagnosis was suspected fortuitously on 
the findings of a CT performed for another aim.
Echocardiography, especially the trans-esophageal 
route, is habitually the initial imaging modality. It may 
show the tumor, its extent and its hemodynamic conse-
quences (Fig. 1). CT scan and cardiac MRI provide fur-
ther information about morphology, location and extent 
of the mass (Fig. 2). Cardiac MRI is more efficient to eval-
uate myocardial involvement. CT scan is useful to assess 
extracardiac extent and metastasis [5].
Cardiac leiomyosarcomas have a high rate of local 
and distant recurrence, occurring even after an optimal 
resection of the primary tumor.
The left atrium is the most frequent location of cardiac 
leiomyosarcomas (51%). That joins operative and radio-
logical findings, in our case.
Biopsy is the gold standard for histological confirma-
tion but this step can sometimes be overtaken and the 
diagnosis is then made on the examination of resected 
mass.
Complete surgical resection, when it’s possible, is the 
mainstay of treatment.
Since soft tissue sarcoma is a heterogeneous group, 
benefits of adjuvant chemotherapy isn’t clearly estab-
lished. Several studies defined subgroups associated 
with a high risk of local and distant relapse. Risk varies 
depending on factors like size >5 cm, high grade, depth 
and chemosensitive histologies with a metastatic poten-
tial. Leiomyosarcoma belongs to the high risk group. 
Major drugs used are Doxorubicin, Ifosfamide and Dac-
arbazine [6]. It’s what leaded us to propose six cycles of 
Doxorubicin and Ifosfamide in adjuvant setting to our 
patient, after a multidisciplinary team consultation.
Fig. 1 Transoesophageal echocardiography showing mid esopha-
geal 20° view. Left atrium tumor. RA right atrium, LA left atrium
Fig. 2 Computed tomography; Transverse section: 6 cm defect 
involving the right atrium and the right inferior pulmonary vein, 
which appears markedly enlarged
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Indications of radiation therapy are mostly restrained to 
palliative setting. It’s proposed when margins of resection 
are positive or for aggressive localized disease or for recur-
rences. Since the lack of evidence concerning the efficacy of 
radiotherapy in management of cardiac leiomyosarcomas 
and the poor tolerance, its use stills equivocal and unusual.
According to the reported cases of leiomyosarcomas 
with cardiac involvement, the mean survival time of 
patients who underwent surgery and chemotherapy was 
about 12  months [6]. Several factors are suspected to 
enworse the prognosis particularly the high grade, a high 
mitotic index, positive surgical margins and metastasis [7].
In the case above, our patient had a grade 3 tumor with 
a high mitotic activity. She underwent a carcinologic 
surgery and adjuvant chemotherapy. Currently, she is 
still alive and there is no evidence of local recurrence or 
metastasis, after a follow-up of 24 months.
Conclusions
Cardiac leiomyosarcoma is a rare tumor with a dismal prog-
nosis. Wide margin resection is the mainstay of treatment. 
For soft tissue sarcoma, adjuvant chemotherapy is still con-
troversial. Nevertheless, leiomyosarcoma belongs to the 
high risk group of soft tissue sarcoma associated with a met-
astatic potential. In this group, there is a trend to outcomes 
improvement with adjuvant chemotherapy. Drugs used in 
this context are Doxorubicin, Ifosfamide and Dacarbazine.
Regarding the scarcity of this disease, it’s important to 
report all cases with a longer follow-up to refine indica-
tions and modalities of adjuvant treatment and prognos-
tic factors.
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